COBO Technologies is a fast-growing start-up company based in Copenhagen, Denmark, that specializes in products and services for Quality Control (QC) of CRISPR modified cells and animals. The team behind COBO comes from senior positions in science, commercial and operation, with more than 10 years experience in the CRISPR field. Within the last 5 years, the CRISPR field has developed from more than 100 publications per year to now more than 5,000 publications per year and the number of ongoing clinical trials using a CRISPR tool is now more than 60. In 2020 two CRISPR scientists received the Nobel Prize in Chemistry for their CRISPR inventions, proving that this is a fast-growing field which is now moving from research to clinics. In consequence, there is a need for platforms that can support efficient QC of CRISPR cells. In more general terms, there is a need to understand what are the safety effects of altering DNA with CRISPR — hitting the right target gene, checking how efficient the DNA change is, and investigating other DNA changes that were not expected. Most of the solutions offered today for cell/DNA analysis are not developed specifically for CRISPR applications. They are expensive, lack sensitivity and are time-consuming and they are done by service companies with no/or little knowledge about CRISPR. Based on our experience from the CRISPR field and feedback from our network in the EU and US, we have developed proprietary platforms that can support the current needs for QC of CRISPR cells. Including both proven reagents for sample preparation, cell analysis and bioinformatics, this is the first full-package solution developed specifically for CRISPR clients. In addition, it combines low cost, high sensitivity and fast delivery time - 3 factors essential for our clients. We have used the past year to build up a scalable operation in Denmark in a low-risk setup and are now ready to speed up the growth first in the EU and then later 2021 in the US. In addition, we will also start the initial preparation of our first development project for a clinical application at the end of 2021. Since the start 2018, COBO has supported more than 15 clients in both EU and US, including leading pharma companies and some of the leading universities in the world. We have developed unique platforms, we have clients every week, we have the network and we have the skills to be a major player in the global CRISPR field and be part of the development of future CRISPR Medicine to treat genetic diseases. As of today, COBO Technologies is backed by an angel investor.